TrialOral oncology2021

Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.

Siyu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.